DROPERIDOL

Post-LOE

droperidol

Teva

ANDAINJECTIONINJECTABLE

Approved

Oct 1988

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DROPERIDOL (droperidol) by Teva is dopamine d2 antagonists [moa]. Approved for nausea, vomiting associated with surgical, diagnostic procedures. First approved in 1988.

Drug data last refreshed 20h ago

Mechanism of Action

Dopamine D2 Antagonists

Pharmacologic Class:

Dopamine-2 Receptor Antagonist

Indications (3)

nausea vomiting associated with surgical diagnostic procedures

Worked on DROPERIDOL at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.